Evidence Level
Alpha Lipoic Acid (Liver Support) is a potent antioxidant with hepatoprotective properties, effective in both aqueous and lipid environments. Packer et al. (1995) demonstrated its ability to regenerate glutathione and other antioxidants, underscoring its role in mitigating oxidative stress. In the context of non-alcoholic fatty liver disease (NAFLD), Koh et al. (2011) conducted a randomized, double-blind, placebo-controlled trial involving 360 obese individuals, revealing that 1800 mg/day of alpha-lipoic acid reduced body weight and liver enzymes, indicating potential benefits for metabolic health. Additionally, studies have shown that alpha-lipoic acid enhances insulin sensitivity, a critical factor in managing fatty liver disease progression. Jacob et al. (1999) reported significant improvements in insulin sensitivity (+27%) among type 2 diabetic patients treated with alpha-lipoic acid compared to placebo in a multicenter pilot study (n=74). The R-enantiomer is the biologically active form, approximately twice as potent as the racemic mixture commonly available. These findings collectively support alpha-lipoic acid's role in liver health and metabolic regulation.